Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Fay

Showing results (351-360 of 395) with videos related to

Pageof 40
Sort By:
American Journal of Physiology. Endocrinology and Metabolism|July 17, 2019
Overproduction of endothelin-1 impairs glucose tolerance but does not promote visceral adipose tissue inflammation or limit metabolic adaptations to exerciseThomas J Jurrissen, Zachary I Grunewald, Makenzie L Woodford, et al.
Lancet (London, England)|July 19, 2025
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trialNeeraj Agarwal, Arun A Azad, Joan Carles, et al.
The Lancet. Haematology|December 22, 2015
Effect of red blood cell variants on childhood malaria in Mali: a prospective cohort studyTatiana M Lopera-Mesa, Saibou Doumbia, Drissa Konaté, et al.
Future Oncology (London, England)|July 12, 2024
Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancerNeeraj Agarwal, Arun A Azad, Joan Carles, et al.
Plos One|October 18, 2007
Impact of a Plasmodium falciparum AMA1 vaccine on antibody responses in adult MaliansAlassane Dicko, David J Diemert, Issaka Sagara, et al.
Vaccine|October 31, 2009
A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adultsIssaka Sagara, Ruth D Ellis, Alassane Dicko, et al.
Clinical Genitourinary Cancer|December 3, 2014
Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma treated with targeted therapies: results from the International mRCC Database ConsortiumAndré P Fay, Wanling L Xie, Jae-Lyn Lee, et al.
Nature Medicine|December 4, 2023
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trialKarim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
The New England Journal of Medicine|April 4, 2019
Benralizumab for <i>PDGFRA</i>-Negative Hypereosinophilic SyndromeFei Li Kuang, Fanny Legrand, Michelle Makiya, et al.
Plos One|October 18, 2016
Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve AdultsKawsar R Talaat, Ruth D Ellis, Janet Hurd, et al.
Pageof 40

Showing results (351-360 of 395) with videos related to

Sort By:
Pageof 40
American Journal of Physiology. Endocrinology and Metabolism|July 17, 2019
Overproduction of endothelin-1 impairs glucose tolerance but does not promote visceral adipose tissue inflammation or limit metabolic adaptations to exerciseThomas J Jurrissen, Zachary I Grunewald, Makenzie L Woodford, et al.
Lancet (London, England)|July 19, 2025
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trialNeeraj Agarwal, Arun A Azad, Joan Carles, et al.
The Lancet. Haematology|December 22, 2015
Effect of red blood cell variants on childhood malaria in Mali: a prospective cohort studyTatiana M Lopera-Mesa, Saibou Doumbia, Drissa Konaté, et al.
Future Oncology (London, England)|July 12, 2024
Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancerNeeraj Agarwal, Arun A Azad, Joan Carles, et al.
Plos One|October 18, 2007
Impact of a Plasmodium falciparum AMA1 vaccine on antibody responses in adult MaliansAlassane Dicko, David J Diemert, Issaka Sagara, et al.
Vaccine|October 31, 2009
A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adultsIssaka Sagara, Ruth D Ellis, Alassane Dicko, et al.
Clinical Genitourinary Cancer|December 3, 2014
Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma treated with targeted therapies: results from the International mRCC Database ConsortiumAndré P Fay, Wanling L Xie, Jae-Lyn Lee, et al.
Nature Medicine|December 4, 2023
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trialKarim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
The New England Journal of Medicine|April 4, 2019
Benralizumab for <i>PDGFRA</i>-Negative Hypereosinophilic SyndromeFei Li Kuang, Fanny Legrand, Michelle Makiya, et al.
Plos One|October 18, 2016
Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve AdultsKawsar R Talaat, Ruth D Ellis, Janet Hurd, et al.
Pageof 40